A team of Yale University scientists has synthesized for the first time a chemical compound called lomaiviticin aglycon, leading to the development of a new class of molecules that appear to target and destroy cancer stem cells. Chemists worldwide have been interested in lomaiviticin’s potential anticancer properties since its discovery in 2001. But so far, ...
Scientists at the Genome Institute of Singapore (GIS), a biomedical research institute of the Agency for Science, Technology and Research (A*STAR), recently identified a new biomarker to predict sensitivity to rapamycin, an immunosuppressive agent that has shown promise as a cancer therapeutic and approved for clinical application; but patients’ response to this class of drugs ...
Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, announced the publication of a research article in Bioorganic & Medicinal Chemistry Letters on the anti-tumor activity of RX-8243 and its analogues. The article offers data demonstrating that RX-8243, an isoquinolineamine analogue, significantly ...
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted antibody-based anticancer products, announced the start of clinical testing with SAR566658. Eight compounds are now in the clinic through ImmunoGen’s product programs and those of its partners, consistent with Company expectations of as many as 12 such compounds being in the clinic by late 2011 ...
There are several challenges to be overcome if therapeutic anticancer vaccines, which are designed to boost the patient’s anticancer immune response, are to be successfully developed. For example, the viruses used to deliver the tumor protein to the patient’s immune system are themselves targeted by the patient’s immune system, inducing neutralizing and suppressive responses. However, ...
